Indivior PLC (NASDAQ:INDV) Sees Significant Decline in Short Interest

Indivior PLC (NASDAQ:INDV) was the recipient of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 1,220,000 shares, a decline of 14.1% from the January 31st total of 1,420,000 shares. Based on an average daily volume of 1,230,000 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.1% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. RODMAN&RENSHAW upgraded shares of Indivior to a “strong-buy” rating in a research note on Tuesday, January 28th. Rodman & Renshaw assumed coverage on shares of Indivior in a research report on Tuesday, January 28th. They set a “buy” rating and a $16.00 price objective for the company. Finally, Piper Sandler decreased their price objective on shares of Indivior from $16.00 to $13.00 and set an “overweight” rating on the stock in a report on Thursday.

Indivior Stock Down 4.3 %

Shares of INDV stock traded down $0.42 on Friday, reaching $9.47. The company had a trading volume of 356,019 shares, compared to its average volume of 577,149. The business’s 50-day moving average is $10.97 and its 200 day moving average is $10.62. The stock has a market capitalization of $1.31 billion, a PE ratio of -27.12 and a beta of 0.82. Indivior has a one year low of $7.33 and a one year high of $22.53.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.32. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The business had revenue of $298.00 million during the quarter, compared to analyst estimates of $262.35 million. On average, sell-side analysts forecast that Indivior will post 1.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Indivior

Institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. bought a new position in Indivior during the 4th quarter worth approximately $359,000. Stifel Financial Corp bought a new stake in Indivior during the third quarter valued at $100,000. AlphaCentric Advisors LLC bought a new position in shares of Indivior in the 3rd quarter worth about $2,364,000. Clark Estates Inc. NY acquired a new stake in Indivior during the third quarter worth approximately $2,477,000. Finally, Valence8 US LP bought a new stake in Indivior in the third quarter worth approximately $564,000. Institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.